Treating MDS: A Look at an Approved Treatment

Guest: Rami Komrokji, MD <br> Guest: Natasha Johnson, MSN, APRN, AOCNP <br> <p>Myelodysplastic syndromes (MDS) can require lifelong treatment.¹Learn how hematologist-oncologist Dr. Rami Komrokji and nurse practitioner Ms. Natasha Johnson approach their MDS protocol–from characterization, to diagnosis, to treatment. Together, they explain their process for scoring, transplants, and choosing a treatment regimen. They also share their experiences with INQOVI® (decitabine and cedazuridine), the only oral hypomethylating agent in the treatment of MDS, including chronic myelomonocytic leukemia.²</p> <div><strong>References:</strong> </div> <div><strong>1. </strong>Platzbecker U. Treatment of MDS. <em>Blood</em>. 2019;133(10):1096-1107. </div> <div><strong>2. </strong>INQOVI [package insert]. Princeton, NJ: Taiho Oncology, Inc.; 2020.</div>